International Journal of Hematology

, Volume 106, Issue 6, pp 794–800 | Cite as

Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma

  • Marta Bielska
  • Maciej Borowiec
  • Dorota Jesionek-Kupnicka
  • Marcin Braun
  • Marcin Bojo
  • Agata Pastorczak
  • Ewa Kalinka-Warzocha
  • Monika Prochorec-Sobieszek
  • Tadeusz Robak
  • Krzysztof Warzocha
  • Wojciech Młynarski
  • Ewa Lech-Marańda
Original Article

Abstract

IKZF1 encodes a transcription factor involved in B-cell maturation and differentiation. We genotyped 218 diffuse large B-cell lymphoma (DLBCL) patients and 715 unrelated controls using a TaqMan allelic discrimination assay. No statistical difference was observed in the genotype distribution of the IKZF1 rs4132601 polymorphism between DLBCL patients and controls. However, the 2-year PFS rate of patients with the IKZF1 TT genotype was 54.3% compared to 68.6% in those with the IKZF1 G+ genotypes. Moreover, the IKZF1 rs4132601 polymorphism retained its independent prognostic impact on PFS. A more pronounced effect of the IKZF1 TT genotype on PFS was detected in patients with low/intermediate low IPI-risk group. When analysis was restricted to patients with GCB-type pattern, those with the IKZF1 TT genotype achieved a lower 5-year OS rate than the patients with the IKZF1 G+ genotypes (19.6 vs. 56%). This study provides the first evidence for the association of IKZF1 variants with DLBCL outcome.

Keywords

IKZF1 Diffuse large B-cell lymphoma Gene polymorphism 

Notes

Author contributions

MBi, AP, MBor, WM designed the experiments. MBi, AP performed the experiments. MBi, WM, ELM analyzed the data. MBoj, ELM collected the clinical data. MBi, MBr, MBoj collected patient material. DJK, EKW, MPS, TR, KW, ELM provided material. MBi, WM, ELM carried out figures/tables preparations. MBi wrote the manuscript. WM, ELM, AP carried out revision. All authors read and approved the final manuscript.

Compliance with ethical standards

Ethics approval and consent to participate

All experimental procedures were approved by the Bioethics Committee of Medical University of Lodz, Poland (RNN/141/13/KE).

Conflict of interest

The authors reported no potential conflicts of interests.

Funding

This work was supported by Grant from National Science Centre (project 2013/09/N/NZ5/00822) and by Medical University of Lodz grant (project 502-03/2-159-02/502-14-195).

Supplementary material

12185_2017_2315_MOESM1_ESM.pdf (218 kb)
Supplementary material 1 (PDF 217 kb)

References

  1. 1.
    Sherborne AL, Houlston RS. What are genome-wide association studies telling us about B-cell tumor development? Oncotarget. 2010;5:367–72.CrossRefGoogle Scholar
  2. 2.
    Pastorczak A, Górniak P, Sherborne A, Hosking F, Trelińska J, Lejman M, et al. Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population. Leuk Res. 2011;35:1534–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41:1006–10.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Górniak P, Pastorczak A, Zalewska-Szewczyk B, Lejman M, Trelińska J, Chmielewska M, et al. Polymorphism in IKZF1 gene affects age at onset of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2014;9:2174–8.CrossRefGoogle Scholar
  5. 5.
    Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–80.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Georgopoulos K. Acute lymphoblastic leukemia—on the wings of IKAROS. N Engl J Med. 2009;360:524–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Katsura Y, Ohta I, Yoshida C, Ohtani H, Komeno T. Diffuse large B-cell lymphoma carrying both t(3;7)(q27;p12) and t(8;14)(q24;q32). Intern Med. 2011;50:905–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Hosokawa Y, Maeda Y, Ichinohasama R, Miura I, Taniwaki M, Seto M. The Ikaros gene, a central regulator of lymphoid differentiation, fuses to the BCL6 gene as a result of t(3;7)(q27;p12) translocation in a patient with diffuse large B-cell lymphoma. Blood. 2000;95:2719–21.PubMedGoogle Scholar
  9. 9.
    Ichinohasama R, Miura I, Funato T, Sato I, Suzuki C, Saito Y, et al. A recurrent nonrandom translocation (3;7)(q27;p12) associated with BCL-6 gene rearrangement in B-cell diffuse large cell lymphoma. Cancer Genet Cytogenet. 1998;104:19–27.CrossRefPubMedGoogle Scholar
  10. 10.
    Enciso-Mora V, Hosking FJ, Sheridan E, Kinsey SE, Lightfoot T, Roman E, et al. Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. 2012;26:2212–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Bartram T, Burkhardt B, Wössmann W, Seidemann K, Zimmermann M, Cario G, et al. Childhood acute lymphoblastic leukemia-associated risk loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin–Frankfurt–Münster Study Group. Leuk Lymphoma. 2014;13:1–3.Google Scholar
  12. 12.
    Hu L, Yu B, Yang J. MDR1 polymorphisms associated with risk and survival in diff use large B-cell lymphoma. Leuk Lymphoma. 2013;54:1188–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim MK, Suh C, Chi HS, Cho HS, Bae YK, Lee KH, et al. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci. 2012;103:497–503.CrossRefPubMedGoogle Scholar
  14. 14.
    Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, et al. Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leuk Lymphoma. 2013;54:2205–14.CrossRefPubMedGoogle Scholar
  15. 15.
    Swafford AD, Howson JM, Dawison LJ, Wallace C, Smyth DJ, Schuilenburg H, et al. An allele of IKZF1 (Ikaros) conferring susceptibility to childhood acute lymphoblastic leukemia protects against type 1 diabetes. Diabetes. 2011;60:1041–4.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 2010;116:e81–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Marta Bielska
    • 1
  • Maciej Borowiec
    • 2
  • Dorota Jesionek-Kupnicka
    • 3
  • Marcin Braun
    • 1
    • 3
    • 4
  • Marcin Bojo
    • 5
  • Agata Pastorczak
    • 1
  • Ewa Kalinka-Warzocha
    • 5
  • Monika Prochorec-Sobieszek
    • 6
  • Tadeusz Robak
    • 7
  • Krzysztof Warzocha
    • 8
  • Wojciech Młynarski
    • 1
  • Ewa Lech-Marańda
    • 8
    • 9
  1. 1.Department of Pediatrics, Oncology, Hematology and DiabetologyMedical University of LodzLodzPoland
  2. 2.Department of Clinical GeneticsMedical University of LodzLodzPoland
  3. 3.Chair of Oncology, Department of PathologyMedical University of LodzLodzPoland
  4. 4.Postgraduate School of Molecular MedicineMedical University of WarsawWarsawPoland
  5. 5.Department of ChemotherapyWojewódzki Szpital Specjalistyczny im. M. KopernikaLodzPoland
  6. 6.Department of Diagnostic HematologyInstitute of Hematology and Transfusion MedicineWarsawPoland
  7. 7.Department of HematologyMedical University of LodzWarsawPoland
  8. 8.Department of HematologyInstitute of Hematology and Transfusion MedicineWarsawPoland
  9. 9.Department of Hematology and Transfusion MedicineCentre of Postgraduate Medical EducationWarsawPoland

Personalised recommendations